世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

ワクチン市場:技術毎(生ワクチン、トキソイド、組換え)、疾患毎(肺炎球菌、インフルエンザ、DTP、HPV、肝炎、髄膜炎菌、ロタウイルス、ポリオ、MMR、水痘、デング熱)、経路毎(筋肉内投与・皮下投与、口内)、患者毎(小児、成人)、タイプ毎 - 2023年までの世界市場予測

Vaccines Market by Technology (Live, Toxoid, Recombinant), Disease (Pneumococcal, Influenza, DTP, HPV, Hepatitis, Meningococcal, Rotavirus, Polio, MMR, Varicella, Dengue), Route (IM/SC, Oral), Patient (Pediatric, Adult), Type - Global Forecast to 2023

 

出版社 出版年月電子版価格 ページ数図表数
MarketsandMarkets
マーケッツアンドマーケッツ
2018年8月US$5,650
シングルユーザライセンス
191 150

サマリー

幅広い市場に関する調査レポートを出版しているマーケッツアンドマーケッツ(MarketsandMarkets)のワクチン市場に関する調査レポートです。

“Global vaccines market projected to grow at a CAGR of 6.7%”

The vaccines market is expected to reach USD 50.42 billion by 2023 from USD 36.45 billion in 2018, at a CAGR of 6.7%. Rising prevalence of diseases, increasing government and nongovernment funding for vaccine development, and increasing company initiatives to enhance R&D are driving the growth of the vaccines market. On the other hand, market growth may be hindered due to the high cost of vaccine development.

“Monovalent vaccines segment expected to hold the largest share of the market in 2018.”

Based on type, the vaccines market is segmented into monovalent vaccines and multivalent vaccines. The monovalent segment is expected to dominate this market with the largest share due to increasing investments by companies to develop new vaccines.

“Pneumococcal disease segment is expected to hold largest share of the market in 2018”

Based on the disease indication, the vaccines market is segmented into pneumococcal disease, influenza, DTP, hepatitis, human papillomavirus (HPV), rotavirus, meningococcal disease, MMR (measles, mumps, and rubella), varicella, polio, herpes zoster, dengue, and other disease indications. The pneumococcal segment is expected to account for the largest share of the vaccines market in 2018. The large share of this segment can primarily be attributed to increasing government investments in pneumococcal vaccination programs and high incidence of pneumococcal diseases.

“Asia to witness high growth during the forecast period”

In 2018, North America is expected to account for the largest share of the market followed by Europe. However, Asia is expected to register the highest CAGR during the forecast period. The high growth in this segment is attributed to the increasing investments by companies in India and China, rising disposable income, growing number of awareness programs and symposia, and growing venture capital investments.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1 – 36%; Tier 2 - 41%; Tier 3 - 23%.
• By Designation (Supply Side): C-level - 25%; D-level - 29%; Others - 46%.
• By Designation (Demand Side): General Physicians - 38%; Purchase Managers - 29%; Medical Researchers - 33%.
• By Region: North America - 40%; Europe - 20%; Asia - 33%; RoW - 7%.

List of companies profiled in the report

• GlaxoSmithKline plc (US)
• Pfizer, Inc. (US)
• Merck & Co., Inc. (US)
• Sanofi Pasteur SA (France)
• CSL Limited (Australia)
• Emergent BioSolutions, Inc. (US)
• Johnson & Johnson (US)
• MedImmune, LLC (US)
• Astellas Pharma Inc. (Japan)
• Serum Institute of India (India)
• Bavarian Nordic (Denmark)
• Mitsubishi Tanabe Pharma Corporation (Japan)
• Daiichi Sankyo Company, Limited (Japan)
• Biological E (India)
• Panacea Biotec (India)

Research Coverage:

The report provides an overview of the vaccines market. It aims at estimating the market size and future growth potential of this market across different segments such as technology, type, disease indication, route of administration, end user, and region. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help the market leaders/new entrants in this market by providing them with the closest approximations of revenues for the overall vaccines market and its subsegments. This report will help stakeholders to understand the competitive landscape better and gain insights to position their businesses and help companies make suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provide them with information regarding key market drivers and opportunities.
 



目次

1 INTRODUCTION 18
1.1 OBJECTIVES OF THE STUDY 18
1.2 MARKET DEFINITION 18
1.3 MARKET SCOPE 19
1.3.1 MARKET COVERED 19
1.3.2 YEARS CONSIDERED FOR THE STUDY 20
1.4 CURRENCY 20
1.5 LIMITATIONS 20
1.6 STAKEHOLDERS 21

2 RESEARCH METHODOLOGY 22
2.1 RESEARCH DESIGN 22
2.1.1 SECONDARY DATA 23
2.1.1.1 Key data from secondary sources 23
2.1.2 PRIMARY DATA 23
2.1.2.1 Key data from primary sources 24
2.1.2.2 Key industry insights 25
2.2 MARKET SIZE ESTIMATION 26
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 29
2.4 MARKET SHARE ESTIMATION 30
2.5 ASSUMPTIONS FOR THE STUDY 30

3 EXECUTIVE SUMMARY 31

4 PREMIUM INSIGHTS 35
4.1 OVERVIEW OF THE VACCINES MARKET 35
4.2 VACCINES MARKET, BY TYPE, 2018–2023 36
4.3 VACCINES MARKET, BY END USER, 2018 VS. 2023 (USD BILLION) 36
4.4 GEOGRAPHIC ANALYSIS: VACCINES MARKET, BY TECHNOLOGY 37
4.5 VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2018 VS. 2023 (USD BILLION) 38
4.6 GEOGRAPHICAL SNAPSHOT OF THE VACCINES MARKET 38

5 MARKET OVERVIEW 39
5.1 INTRODUCTION 39
5.2 MARKET DYNAMICS 39
5.2.1 DRIVERS 40
5.2.1.1 High prevalence of infectious diseases 40
5.2.1.2 Rising focus on immunization programs 40
5.2.1.3 Growing government support for vaccine development 41
5.2.1.4 Increasing company initiatives to enhance vaccine R&D 42
5.2.2 RESTRAINTS 42
5.2.2.1 High cost of vaccine development 42
5.2.3 OPPORTUNITIES 42
5.2.3.1 High growth prospects in emerging markets 42
5.2.3.2 Focus on therapeutic vaccines 43
5.2.3.3 Use of adjuvants in vaccines 43
5.2.4 CHALLENGES 44
5.2.4.1 Inadequate access to vaccines 44
5.2.4.2 Product recalls 45

6 INDUSTRY INSIGHTS 46
6.1 REGULATORY LANDSCAPE 46
6.1.1 NORTH AMERICA 47
6.1.2 EUROPE 47
6.1.3 ASIA 48
6.1.4 ROW 48
6.2 KEY PIPELINE PRODUCTS 49
6.3 NEW VACCINE OPPORTUNITIES 50
6.3.1 HIV 50
6.3.1.1 HIV vaccine: product pipeline 50
6.3.1.2 HIV vaccine: public-private initiatives 51
6.3.1.3 HIV vaccine: funding 51
6.3.2 MALARIA 53
6.3.2.1 Malaria vaccine: product pipeline 53
6.3.2.2 Malaria vaccine: public-private initiatives 54
6.3.3 ZIKA 54
6.3.3.1 Zika vaccine: product pipeline 54
6.3.3.2 Zika vaccine: public-private initiatives 55
6.3.3.3 Zika vaccine: funding 55
6.3.4 EBOLA 55
6.3.4.1 Ebola vaccine: product pipeline 55
6.3.4.2 Ebola vaccine: public-private initiatives 56
6.3.4.3 Ebola vaccine: funding 56

7 VACCINES MARKET, BY TECHNOLOGY 57
7.1 INTRODUCTION 58
7.2 CONJUGATE VACCINES 59
7.3 INACTIVATED AND SUBUNIT VACCINES 60
7.4 LIVE ATTENUATED VACCINES 61
7.5 RECOMBINANT VACCINES 62
7.6 TOXOID VACCINES 63

8 VACCINES MARKET, BY TYPE 65
8.1 INTRODUCTION 66
8.2 MONOVALENT VACCINES 67
8.3 MULTIVALENT VACCINES 68

9 VACCINES MARKET, BY DISEASE INDICATION 70
9.1 INTRODUCTION 71
9.2 PNEUMOCOCCAL DISEASE 73
9.3 DTP 74
9.4 INFLUENZA 75
9.5 HPV 76
9.6 MENINGOCOCCAL DISEASE 77
9.7 POLIO 79
9.8 ROTAVIRUS 80
9.9 HEPATITIS 81
9.10 MMR 82
9.11 VARICELLA 83
9.12 DENGUE 84
9.13 HERPES ZOSTER 85
9.14 OTHER DISEASE INDICATIONS 86

10 VACCINES MARKET, BY ROUTE OF ADMINISTRATION 88
10.1 INTRODUCTION 89
10.2 INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION 90
10.3 ORAL ADMINISTRATION 91
10.4 OTHER ROUTES OF ADMINISTRATION 91

11 VACCINES MARKET, BY PATIENT TYPE 93
11.1 INTRODUCTION 94
11.2 PEDIATRIC PATIENTS 95
11.3 ADULT PATIENTS 96

12 VACCINES MARKET, BY REGION 98
12.1 INTRODUCTION 99
12.2 NORTH AMERICA 99
12.2.1 US 103
12.2.2 CANADA 104
12.3 EUROPE 105
12.3.1 GERMANY 109
12.3.2 UK 110
12.3.3 FRANCE 111
12.3.4 ITALY 112
12.3.5 SPAIN 113
12.3.6 ROE 113
12.4 ASIA 115
12.4.1 JAPAN 119
12.4.2 CHINA 120
12.4.3 INDIA 121
12.4.4 REST OF ASIA (ROA) 122
12.5 REST OF THE WORLD (ROW) 123
12.5.1 LATIN AMERICA 126
12.5.2 OTHER ROW COUNTRIES 129

13 COMPETITIVE LANDSCAPE 133
13.1 OVERVIEW 133
13.2 MARKET SHARE ANALYSIS 134
13.3 COMPETITIVE SITUATION AND TRENDS 136
13.3.1 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 136
13.3.2 PRODUCT LAUNCHES AND APPROVALS 137
13.3.3 ACQUISITIONS 137
13.3.4 EXPANSIONS 138

14 COMPANY PROFILES 139
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
14.1 PFIZER 139
14.2 GLAXOSMITHKLINE 143
14.3 MERCK 147
14.4 SANOFI PASTEUR 150
14.5 CSL LIMITED 154
14.6 EMERGENT BIOSOLUTIONS 157
14.7 JOHNSON & JOHNSON 160
14.8 MEDIMMUNE, LLC (A SUBSIDIARY OF ASTRAZENECA) 163
14.9 ASTELLAS PHARMA 165
14.10 SERUM INSTITUTE OF INDIA 167
14.11 BAVARIAN NORDIC 170
14.12 MITSUBISHI TANABE PHARMA CORPORATION 173
14.13 DAIICHI SANKYO COMPANY 176
14.14 PANACEA BIOTEC 179
14.15 BIOLOGICAL E 182
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

15 APPENDIX 184
15.1 DISCUSSION GUIDE 184
15.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 187
15.3 AVAILABLE CUSTOMIZATIONS 189
15.4 RELATED REPORTS 189
15.5 AUTHOR DETAILS 190

 

LIST OF TABLES

TABLE 1 INCIDENCE OF DISEASES 40
TABLE 2 NIH FUNDING FOR VACCINE RESEARCH, 2013–2018 (USD MILLION) 41
TABLE 3 IMMUNIZATION COVERAGE, BY DISEASE, 2015 VS 2016 44
TABLE 4 REGULATORY AUTHORITIES IN EUROPE 47
TABLE 5 REGULATORY AUTHORITIES IN ASIA 48
TABLE 6 KEY PIPELINE VACCINES 49
TABLE 7 ESTIMATED INVESTMENTS IN HIV VACCINES, BY INVESTOR (2015–2016) 52
TABLE 8 EBOLA PROJECTS FUNDED BY EC (2014–2020) 56
TABLE 9 VACCINES MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 58
TABLE 10 COST OF MENINGOCOCCAL CONJUGATE VACCINES 59
TABLE 11 CONJUGATE VACCINES MARKET, BY REGION, 2016–2023 (USD MILLION) 60
TABLE 12 EXAMPLES OF INACTIVATED AND SUBUNIT VACCINES 61
TABLE 13 INACTIVATED AND SUBUNIT VACCINES MARKET, BY REGION,
2016–2023 (USD MILLION) 61
TABLE 14 LIVE ATTENUATED VACCINES MARKET, BY REGION, 2016–2023 (USD MILLION) 62
TABLE 15 EXAMPLES OF RECOMBINANT VACCINES 63
TABLE 16 RECOMBINANT VACCINES MARKET, BY REGION, 2016–2023 (USD MILLION) 63
TABLE 17 TOXOID VACCINES MARKET, BY REGION, 2016–2023 (USD MILLION) 64
TABLE 18 VACCINES MARKET, BY TYPE, 2016–2023 (USD MILLION) 66
TABLE 19 MONOVALENT VACCINES MARKET, BY REGION, 2016–2023 (USD MILLION) 67
TABLE 20 EXAMPLES OF NOTABLE MULTIVALENT VACCINES AVAILABLE IN THE MARKET 68
TABLE 21 MULTIVALENT VACCINES MARKET, BY REGION, 2016–2023 (USD MILLION) 69
TABLE 22 VACCINES MARKET, BY DISEASE INDICATION, 2016–2023 (USD MILLION) 72
TABLE 23 LIST OF COMMERCIALLY AVAILABLE PNEUMOCOCCAL VACCINES IN THE MARKET 73
TABLE 24 VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY REGION,
2016–2023 (USD MILLION) 74
TABLE 25 LIST OF COMMERCIALLY AVAILABLE DTP VACCINES IN THE MARKET 74
TABLE 26 VACCINES MARKET FOR DTP, BY REGION, 2016–2023 (USD MILLION) 75
TABLE 27 LIST OF COMMERCIALLY AVAILABLE INFLUENZA VACCINES IN THE MARKET 76
TABLE 28 VACCINES MARKET FOR INFLUENZA, BY REGION, 2016–2023 (USD MILLION) 76
TABLE 29 LIST OF COMMERCIALLY AVAILABLE HPV VACCINES IN THE MARKET 77
TABLE 30 VACCINES MARKET FOR HPV, BY REGION, 2016–2023 (USD MILLION) 77
TABLE 31 LIST OF COMMERCIALLY AVAILABLE HPV VACCINES IN THE MARKET 78
TABLE 32 VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY REGION,
2016–2023 (USD MILLION) 78
TABLE 33 LIST OF COMMERCIALLY AVAILABLE POLIO VACCINES IN THE MARKET 79
TABLE 34 VACCINES MARKET FOR POLIO, BY REGION, 2016–2023 (USD MILLION) 80
TABLE 35 LIST OF COMMERCIALLY AVAILABLE ROTAVIRUS VACCINES IN THE MARKET 80
TABLE 36 VACCINES MARKET FOR ROTAVIRUS, BY REGION, 2016–2023 (USD MILLION) 80
TABLE 37 LIST OF COMMERCIALLY AVAILABLE HEPATITIS VACCINES IN THE MARKET 81
TABLE 38 VACCINES MARKET FOR HEPATITIS, BY REGION, 2016–2023 (USD MILLION) 81
TABLE 39 LIST OF COMMERCIALLY AVAILABLE MMR VACCINES IN THE MARKET 82
TABLE 40 VACCINES MARKET FOR MMR, BY REGION, 2016–2023 (USD MILLION) 82
TABLE 41 LIST OF COMMERCIALLY AVAILABLE VARICELLA VACCINES IN THE MARKET 83
TABLE 42 VACCINES MARKET FOR VARICELLA, BY REGION, 2016–2023 (USD MILLION) 83
TABLE 43 VACCINES MARKET FOR HERPES ZOSTER, BY REGION, 2016–2023 (USD MILLION) 85
TABLE 44 LIST OF COMMERCIALLY AVAILABLE VACCINES FOR OTHER DISEASE INDICATIONS IN THE MARKET 86
TABLE 45 VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY REGION,
2016–2023 (USD MILLION) 87
TABLE 46 VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2016–2023 (USD MILLION) 89
TABLE 47 VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY REGION, 2016–2023 (USD MILLION) 90
TABLE 48 VACCINES MARKET FOR ORAL ADMINISTRATION, BY REGION,
2016–2023 (USD MILLION) 91
TABLE 49 VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION,
2016–2023 (USD MILLION) 92
TABLE 50 VACCINES MARKET, BY PATIENT TYPE, 2016–2023 (USD MILLION) 94
TABLE 51 VACCINES MARKET FOR PEDIATRIC PATIENTS, BY REGION,
2016–2023 (USD MILLION) 95
TABLE 52 NORTH AMERICA: VACCINES MARKET FOR PEDIATRIC PATIENTS, BY COUNTRY, 2016–2023 (USD MILLION) 96
TABLE 53 VACCINES MARKET FOR ADULT PATIENTS, BY REGION, 2016–2023 (USD MILLION) 97
TABLE 54 NORTH AMERICA: VACCINES MARKET FOR ADULT PATIENTS, BY COUNTRY,
2016–2023 (USD MILLION) 97
TABLE 55 VACCINES MARKET, BY REGION, 2016–2023 (USD MILLION) 99
TABLE 56 NORTH AMERICA: VACCINES MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 101
TABLE 57 NORTH AMERICA: VACCINES MARKET, BY TECHNOLOGY,
2016–2023 (USD MILLION) 101
TABLE 58 NORTH AMERICA: VACCINES MARKET, BY TYPE, 2016–2023 (USD MILLION) 101
TABLE 59 NORTH AMERICA: VACCINES MARKET, 2016–2023 (USD MILLION) 102
TABLE 60 NORTH AMERICA: VACCINES MARKET, 2016–2023 (USD MILLION) 102
TABLE 61 NORTH AMERICA: VACCINES MARKET, BY PATIENT TYPE,
2016–2023 (USD MILLION) 103
TABLE 62 US: VACCINES MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 104
TABLE 63 US: VACCINES MARKET, BY PATIENT TYPE, 2016–2023 (USD MILLION) 104
TABLE 64 CANADA: VACCINES MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 105
TABLE 65 CANADA: VACCINES MARKET, BY PATIENT TYPE, 2016–2023 (USD MILLION) 105
TABLE 66 EUROPE: VACCINES MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 107
TABLE 67 EUROPE: VACCINES MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 107
TABLE 68 EUROPE: VACCINES MARKET, BY TYPE, 2016–2023 (USD MILLION) 107
TABLE 69 EUROPE: VACCINES MARKET, BY DISEASE INDICATION,
2016–2023 (USD MILLION) 108
TABLE 70 EUROPE: VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2016–2023 (USD MILLION) 109
TABLE 71 EUROPE: VACCINES MARKET, BY PATIENT TYPE, 2016–2023 (USD MILLION) 109
TABLE 72 GERMANY: VACCINES MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 110
TABLE 73 UK: VACCINES MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 111
TABLE 74 FRANCE: VACCINES MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 112
TABLE 75 ITALY: VACCINES MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 112
TABLE 76 SPAIN: VACCINES MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 113
TABLE 77 ROE: VACCINES MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 114
TABLE 78 ASIA: HEALTH EXPENDITURE PER CAPITA, BY COUNTRY, 2000, 2014 & 2016 (USD) 115
TABLE 79 ASIA: VACCINES MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 117
TABLE 80 ASIA: VACCINES MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 117
TABLE 81 ASIA: VACCINES MARKET, BY TYPE, 2016–2023 (USD MILLION) 117
TABLE 82 ASIA: VACCINES MARKET, BY DISEASE INDICATION, 2016–2023 (USD MILLION) 118
TABLE 83 ASIA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2016–2023 (USD MILLION) 118
TABLE 84 ASIA: VACCINES MARKET, BY PATIENT TYPE, 2016–2023 (USD MILLION) 119
TABLE 85 JAPAN: VACCINES MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 119
TABLE 86 CHINA: VACCINES MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 120
TABLE 87 INDIA: VACCINES MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 121
TABLE 88 ROA: VACCINES MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 122
TABLE 89 ROW: VACCINES MARKET, BY REGION, 2016–2023 (USD MILLION) 124
TABLE 90 ROW: VACCINES MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION) 124
TABLE 91 ROW: VACCINES MARKET, BY TYPE, 2016–2023 (USD MILLION) 124
TABLE 92 ROW: VACCINES MARKET, 2016–2023 (USD MILLION) 125
TABLE 93 ROW: VACCINES MARKET, 2016–2023 (USD MILLION) 125
TABLE 94 ROW: VACCINES MARKET, BY PATIENT TYPE, 2016–2023 (USD MILLION) 126
TABLE 95 LATIN AMERICA: VACCINES MARKET, BY TECHNOLOGY,
2016–2023 (USD MILLION) 127
TABLE 96 LATIN AMERICA: VACCINES MARKET, BY TYPE, 2016–2023 (USD MILLION) 127
TABLE 97 LATIN AMERICA: VACCINES MARKET, BY DISEASE INDICATION,
2016–2023 (USD MILLION) 128
TABLE 98 LATIN AMERICA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2016–2023 (USD MILLION) 128
TABLE 99 LATIN AMERICA: VACCINES MARKET, BY PATIENT TYPE,
2016–2023 (USD MILLION) 129
TABLE 100 OTHER ROW COUNTRIES: VACCINES MARKET, BY TECHNOLOGY,
2016–2023 (USD MILLION) 130
TABLE 101 OTHER ROW COUNTRIES: VACCINES MARKET, BY TYPE,
2016–2023 (USD MILLION) 130
TABLE 102 OTHER ROW COUNTRIES: VACCINES MARKET, BY DISEASE INDICATION,
2016–2023 (USD MILLION) 131
TABLE 103 OTHER ROW COUNTRIES: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2016–2023 (USD MILLION) 131
TABLE 104 OTHER ROW COUNTRIES: VACCINES MARKET, BY PATIENT TYPE,
2016–2023 (USD MILLION) 132

 

LIST OF FIGURES

FIGURE 1 VACCINES MARKET SEGMENTATION 19
FIGURE 2 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 26
FIGURE 3 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 27
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 28
FIGURE 5 DATA TRIANGULATION METHODOLOGY 29
FIGURE 6 VACCINES MARKET, BY TECHNOLOGY, 2018–2023 31
FIGURE 7 VACCINES MARKET, BY TYPE, 2018 VS. 2023 (USD BILLION) 32
FIGURE 8 VACCINES MARKET, BY DISEASE INDICATION, 2018 VS. 2023 (USD BILLION) 32
FIGURE 9 VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2018 VS. 2023 (USD BILLION) 33
FIGURE 10 VACCINES MARKET, BY PATIENT TYPE, 2018 VS. 2023 (USD BILLION) 33
FIGURE 11 GEOGRAPHICAL SNAPSHOT OF THE VACCINES MARKET 34
FIGURE 12 HIGH PREVALENCE OF DISEASES AND RISING FOCUS ON IMMUNIZATION PROGRAMS ARE DRIVING MARKET GROWTH 35
FIGURE 13 MONOVALENT VACCINES SEGMENT TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD 36
FIGURE 14 PEDIATRICS SEGMENT TO DOMINATE THE VACCINES MARKET IN
2023 (USD BILLION) 36
FIGURE 15 CONJUGATE VACCINES SEGMENT TO HOLD LARGEST SHARE OF THE VACCINES MARKET IN 2018 37
FIGURE 16 INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION SEGMENT TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD 38
FIGURE 17 US TO DOMINATE THE VACCINES MARKET IN 2018 38
FIGURE 18 VACCINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 39
FIGURE 19 REGULATORY APPROVAL PROCESS FOR VACCINES 46
FIGURE 20 R&D FUNDING FOR HIV PREVENTIVE VACCINES, BY INVESTOR, 2016 52
FIGURE 21 CONJUGATE VACCINES SEGMENT TO DOMINATE THE VACCINES MARKET DURING THE FORECAST PERIOD 58
FIGURE 22 MONOVALENT VACCINES TO GROW AT THE HIGHEST RATE IN THE VACCINES MARKET, BY TYPE 66
FIGURE 23 PNEUMOCOCCAL DISEASE SEGMENT TO LEAD VACCINES MARKET, BY DISEASE INDICATION, DURING 2018–2023 71
FIGURE 24 VACCINES MARKET FOR DENGUE, 2016–2023 (USD MILLION) 85
FIGURE 25 INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION SEGMENT TO ACCOUNT FOR THE VACCINES MARKET, 2018–2023 (USD MILLION) 89
FIGURE 26 PEDIATRIC PATIENTS SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE VACCINES MARKET, 2018 (USD MILLION) 94
FIGURE 27 NORTH AMERICA: VACCINES MARKET SNAPSHOT 100
FIGURE 28 EUROPE: VACCINES MARKET SNAPSHOT 106
FIGURE 29 ASIA: VACCINES MARKET SNAPSHOT 116
FIGURE 30 ROW: VACCINES MARKET SNAPSHOT 123
FIGURE 31 KEY DEVELOPMENTS IN THE VACCINE MARKET FROM 2015 TO 2018 133
FIGURE 32 MARKET EVOLUTION FRAMEWORK 134
FIGURE 33 VACCINES MARKET SHARE ANALYSIS, BY KEY PLAYER, 2017 135
FIGURE 34 PFIZER: COMPANY SNAPSHOT (2017) 139
FIGURE 35 GLAXOSMITHKLINE: COMPANY SNAPSHOT (2017) 143
FIGURE 36 MERCK: COMPANY SNAPSHOT (2017) 147
FIGURE 37 SANOFI PASTEUR: COMPANY SNAPSHOT (2017) 150
FIGURE 38 CSL LIMITED: COMPANY SNAPSHOT (2017) 154
FIGURE 39 EMERGENT BIOSOLUTIONS: COMPANY SNAPSHOT (2017) 157
FIGURE 40 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2017) 160
FIGURE 41 ASTRAZENECA: COMPANY SNAPSHOT (2017) 163
FIGURE 42 ASTELLAS PHARMA: COMPANY SNAPSHOT (2017) 165
FIGURE 43 BAVARIAN NORDIC: COMPANY SNAPSHOT (2017) 170
FIGURE 44 MITSUBISHI TANABE PHARMA CORPORATION: COMPANY SNAPSHOT (2017) 173
FIGURE 45 DAIICHI SANKYO COMPANY: COMPANY SNAPSHOT (2017) 176
FIGURE 46 PANACEA BIOTEC: COMPANY SNAPSHOT (2017) 179
 

 

ページTOPに戻る

プレスリリース

[プレスリリース原文]

Vaccines Market worth $50.42 billion by 2023


August 14, 2018

The report "Vaccines Market by Technology (Live, Toxoid, Recombinant), Disease (Pneumococcal, Influenza, DTP, HPV, Hepatitis, Meningococcal, Rotavirus, Polio, MMR, Varicella, Dengue), Route (IM/SC, Oral), Patient (Pediatric, Adult), Type - Global Forecast to 2023", The vaccines market is expected to reach USD 50.42 billion by 2023 from USD 36.45 billion in 2018, at a CAGR of 6.7%. The growth of the market is attributed to the rising prevalence of diseases, increasing government and nongovernment funding for vaccine development, and increasing companies initiatives to enhance R&D.

Conjugate vaccines to dominate the market in 2018

Based on technology, the vaccines market is segmented into conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, and toxoid vaccines. In 2018, the conjugate segment is expected to account for the largest share of the vaccines market. The growth in this market is mainly driven by increasing investments by the government of developing countriesand rising prevalence of infectious diseases.

Based on disease indication, the meningococcal segment is projected to grow at the highest CAGR during the forecast period.

By disease indication, the vaccines market is segmented into pneumococcal disease, influenza, DTP, hepatitis, human papillomavirus (HPV), rotavirus, meningococcal disease, MMR (measles, mumps, and rubella), varicella, polio, herpes zoster, dengue, and other disease indications. The meningococcal segment is expected to register the highest rate during the forecast period. The growth in this segment can primarily be attributed to the increasing government investments in meningococcal vaccination programs and high prevalence of meningococcal disease.

North America to dominate the vaccines market

In 2018, North America is expected to dominate the market. The large share of this geographical segment is attributed to factors such as increasing investments by government organizations and companies to promote immunization as well as develop new vaccines. Europe is expected to hold the second largest share of this market. Factors such as availability of funding and venture capital investments for the development of new vaccines and increasing government initiatives are expected to drive market growth in this region.

The vaccines market is highly competitive with the presence of several small and big players. Some of the players in the vaccines market are GlaxoSmithKline plc (UK), Pfizer, Inc. (US), Merck & Co., Inc. (US), Sanofi Pasteur SA (France), CSL Limited (Australia), Emergent BioSolutions, Inc. (US), Johnson & Johnson (US), MedImmune, LLC (US), Astellas Pharma Inc. (Japan), Serum Institute of India (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), and Daiichi Sankyo Company, Limited (Japan). 

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る